AU2014274670B2 - Marker for acid sphingomyelinase disorders and uses thereof - Google Patents

Marker for acid sphingomyelinase disorders and uses thereof Download PDF

Info

Publication number
AU2014274670B2
AU2014274670B2 AU2014274670A AU2014274670A AU2014274670B2 AU 2014274670 B2 AU2014274670 B2 AU 2014274670B2 AU 2014274670 A AU2014274670 A AU 2014274670A AU 2014274670 A AU2014274670 A AU 2014274670A AU 2014274670 B2 AU2014274670 B2 AU 2014274670B2
Authority
AU
Australia
Prior art keywords
dose
spm
lyso
subject
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014274670A
Other languages
English (en)
Other versions
AU2014274670A1 (en
Inventor
Wei-Lien Chuang
Gerald F. Cox
X. Kate Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2014274670A1 publication Critical patent/AU2014274670A1/en
Application granted granted Critical
Publication of AU2014274670B2 publication Critical patent/AU2014274670B2/en
Priority to AU2018200977A priority Critical patent/AU2018200977B2/en
Priority to AU2020257114A priority patent/AU2020257114B2/en
Priority to AU2023201062A priority patent/AU2023201062B2/en
Priority to AU2025220876A priority patent/AU2025220876A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
AU2014274670A 2013-06-07 2014-06-06 Marker for acid sphingomyelinase disorders and uses thereof Active AU2014274670B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2018200977A AU2018200977B2 (en) 2013-06-07 2018-02-09 Marker for acid sphingomyelinase disorders and uses thereof
AU2020257114A AU2020257114B2 (en) 2013-06-07 2020-10-22 Marker for acid sphingomyelinase disorders and uses thereof
AU2023201062A AU2023201062B2 (en) 2013-06-07 2023-02-23 Marker for acid sphingomyelinase disorders and uses thereof
AU2025220876A AU2025220876A1 (en) 2013-06-07 2025-08-25 Marker for acid sphingomyelinase disorders and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361832302P 2013-06-07 2013-06-07
US61/832,302 2013-06-07
PCT/US2014/041405 WO2014197859A1 (en) 2013-06-07 2014-06-06 Marker for acid sphingomyelinase disorders and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018200977A Division AU2018200977B2 (en) 2013-06-07 2018-02-09 Marker for acid sphingomyelinase disorders and uses thereof

Publications (2)

Publication Number Publication Date
AU2014274670A1 AU2014274670A1 (en) 2016-01-07
AU2014274670B2 true AU2014274670B2 (en) 2017-11-09

Family

ID=51062988

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2014274670A Active AU2014274670B2 (en) 2013-06-07 2014-06-06 Marker for acid sphingomyelinase disorders and uses thereof
AU2018200977A Active AU2018200977B2 (en) 2013-06-07 2018-02-09 Marker for acid sphingomyelinase disorders and uses thereof
AU2020257114A Active AU2020257114B2 (en) 2013-06-07 2020-10-22 Marker for acid sphingomyelinase disorders and uses thereof
AU2023201062A Active AU2023201062B2 (en) 2013-06-07 2023-02-23 Marker for acid sphingomyelinase disorders and uses thereof
AU2025220876A Pending AU2025220876A1 (en) 2013-06-07 2025-08-25 Marker for acid sphingomyelinase disorders and uses thereof

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2018200977A Active AU2018200977B2 (en) 2013-06-07 2018-02-09 Marker for acid sphingomyelinase disorders and uses thereof
AU2020257114A Active AU2020257114B2 (en) 2013-06-07 2020-10-22 Marker for acid sphingomyelinase disorders and uses thereof
AU2023201062A Active AU2023201062B2 (en) 2013-06-07 2023-02-23 Marker for acid sphingomyelinase disorders and uses thereof
AU2025220876A Pending AU2025220876A1 (en) 2013-06-07 2025-08-25 Marker for acid sphingomyelinase disorders and uses thereof

Country Status (29)

Country Link
US (4) US10022428B2 (cg-RX-API-DMAC7.html)
EP (2) EP3004896B1 (cg-RX-API-DMAC7.html)
JP (4) JP6457501B2 (cg-RX-API-DMAC7.html)
KR (3) KR102292298B1 (cg-RX-API-DMAC7.html)
CN (2) CN105474017A (cg-RX-API-DMAC7.html)
AU (5) AU2014274670B2 (cg-RX-API-DMAC7.html)
CA (1) CA2914751C (cg-RX-API-DMAC7.html)
CL (1) CL2015003563A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150638A (cg-RX-API-DMAC7.html)
DK (1) DK3004896T3 (cg-RX-API-DMAC7.html)
EA (1) EA035342B1 (cg-RX-API-DMAC7.html)
ES (1) ES2762608T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20192246T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047863T2 (cg-RX-API-DMAC7.html)
IL (3) IL284102B2 (cg-RX-API-DMAC7.html)
LT (1) LT3004896T (cg-RX-API-DMAC7.html)
MA (1) MA38638B1 (cg-RX-API-DMAC7.html)
MX (1) MX370570B (cg-RX-API-DMAC7.html)
MY (1) MY185990A (cg-RX-API-DMAC7.html)
NZ (1) NZ754328A (cg-RX-API-DMAC7.html)
PH (1) PH12015502687A1 (cg-RX-API-DMAC7.html)
PL (1) PL3004896T3 (cg-RX-API-DMAC7.html)
PT (1) PT3004896T (cg-RX-API-DMAC7.html)
RS (1) RS59677B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201709925SA (cg-RX-API-DMAC7.html)
SI (1) SI3004896T1 (cg-RX-API-DMAC7.html)
UA (1) UA120591C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014197859A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201508630B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2470199T3 (pl) * 2009-08-28 2019-11-29 Icahn School Med Mount Sinai Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy
EP3004896B1 (en) * 2013-06-07 2019-09-18 Genzyme Corporation Marker for acid sphingomyelinase disorders and uses thereof
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
ES2970423T3 (es) * 2017-08-24 2024-05-28 Genzyme Corp Esfingomielinasa ácida humana recombinante para su uso en el tratamiento de afecciones óseas anormales en pacientes con deficiencia de esfingomielinasa ácida
EP3692070A1 (en) 2017-10-02 2020-08-12 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
JP7568648B2 (ja) * 2019-05-31 2024-10-16 ジェンザイム・コーポレーション 二次元ｌｃ－ｍｓ／ｍｓシステム
EP4562432A2 (en) * 2022-07-28 2025-06-04 Wylder Nation Foundation Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072060A2 (en) * 2011-11-15 2013-05-23 Centogene Gmbh Method for the diagnosis of niemann-pick disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
WO2002018539A2 (en) 2000-08-25 2002-03-07 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
JP2006214731A (ja) 2005-02-01 2006-08-17 Institute Of Physical & Chemical Research スフィンゴミエリンの検出方法
CN101356283A (zh) 2005-12-15 2009-01-28 纽约州立大学研究基金会 用于测量血浆和组织鞘磷脂和磷脂酰胆碱的酶促方法
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US8026099B2 (en) 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders
US8497122B2 (en) 2008-04-11 2013-07-30 Washington University Biomarkers for Niemann-pick C disease and related disorders
PL2470199T3 (pl) * 2009-08-28 2019-11-29 Icahn School Med Mount Sinai Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy
JP2013002933A (ja) 2011-06-16 2013-01-07 Hitachi Plant Technologies Ltd ３次元測位システム
TR201906195T4 (tr) * 2013-05-14 2019-05-21 Centogene Ag Niemann pıck hastalığının teşhisi için metot.
EP3004896B1 (en) * 2013-06-07 2019-09-18 Genzyme Corporation Marker for acid sphingomyelinase disorders and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072060A2 (en) * 2011-11-15 2013-05-23 Centogene Gmbh Method for the diagnosis of niemann-pick disease

Also Published As

Publication number Publication date
KR102434244B1 (ko) 2022-08-19
MX370570B (es) 2019-12-17
MY185990A (en) 2021-06-14
EA201592265A1 (ru) 2016-04-29
IL284102A (en) 2021-07-29
AU2023201062B2 (en) 2025-05-29
KR20210104177A (ko) 2021-08-24
CN105474017A (zh) 2016-04-06
AU2025220876A1 (en) 2025-09-11
EA035342B1 (ru) 2020-05-29
AU2014274670A1 (en) 2016-01-07
US20160120958A1 (en) 2016-05-05
SG10201709925SA (en) 2017-12-28
PH12015502687A1 (en) 2016-03-07
KR102228367B1 (ko) 2021-03-16
AU2018200977B2 (en) 2020-07-23
AU2023201062A1 (en) 2023-03-23
ES2762608T3 (es) 2020-05-25
WO2014197859A1 (en) 2014-12-11
PT3004896T (pt) 2019-12-23
ZA201508630B (en) 2020-01-29
KR20160018651A (ko) 2016-02-17
BR112015030099A2 (pt) 2017-07-25
JP2024038145A (ja) 2024-03-19
HK1217534A1 (en) 2017-01-13
CA2914751C (en) 2023-10-03
IL298675B1 (en) 2025-08-01
SI3004896T1 (sl) 2020-01-31
JP2019089767A (ja) 2019-06-13
JP7414750B2 (ja) 2024-01-16
HRP20192246T1 (hr) 2020-03-06
CA2914751A1 (en) 2014-12-11
CR20150638A (es) 2016-02-08
IL242964B (en) 2021-07-29
JP6835806B2 (ja) 2021-02-24
EP3004896B1 (en) 2019-09-18
US10022428B2 (en) 2018-07-17
JP2021075544A (ja) 2021-05-20
MA38638B1 (fr) 2018-03-30
MA38638A1 (fr) 2017-02-28
RS59677B1 (sr) 2020-01-31
NZ715001A (en) 2021-10-29
PL3004896T3 (pl) 2020-04-30
US11998592B2 (en) 2024-06-04
AU2020257114B2 (en) 2023-03-16
MX2015016844A (es) 2016-04-04
KR20210031541A (ko) 2021-03-19
US20240398907A1 (en) 2024-12-05
IL298675A (en) 2023-01-01
CN115128287A (zh) 2022-09-30
US20210162021A1 (en) 2021-06-03
IL298675B2 (en) 2025-12-01
JP6457501B2 (ja) 2019-01-23
JP2016526050A (ja) 2016-09-01
EP3584580A1 (en) 2019-12-25
UA120591C2 (uk) 2020-01-10
KR102292298B1 (ko) 2021-08-24
HUE047863T2 (hu) 2020-05-28
LT3004896T (lt) 2020-01-10
IL284102B2 (en) 2023-04-01
EP3004896A1 (en) 2016-04-13
CL2015003563A1 (es) 2016-08-05
US10888607B2 (en) 2021-01-12
SG11201509622WA (en) 2015-12-30
US20180289778A1 (en) 2018-10-11
AU2018200977A1 (en) 2018-03-01
DK3004896T3 (da) 2020-01-06
IL284102B (en) 2022-12-01
AU2020257114A1 (en) 2020-11-19
NZ754328A (en) 2021-12-24

Similar Documents

Publication Publication Date Title
AU2023201062B2 (en) Marker for acid sphingomyelinase disorders and uses thereof
HK40021352A (en) Recombinant human acid sphingomyelinase for use in treating human asmd
NZ715001B2 (en) Marker for acid sphingomyelinase disorders and uses thereof
HK1217534B (en) Marker for acid sphingomyelinase disorders and uses thereof
OA17663A (en) Marker for acid sphingomyelinase disorders and uses thereof.
BR112015030099B1 (pt) Método in vitro para determinar a eficácia ou toxicidade de umaesfingomielinase ácida humana recombinante (rhasm) ou dose de rhasmmodificada para o tratamento de uma deficiência de esfingomielinase ácida(asmd) em um indivíduo

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)